TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
Recognition illustrates Takeda’s patient-centricity throughout its manufacturing and supply processes
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
Serina has over 17 years of experience in the biopharmaceutical industry
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
It was recognized for its holistic initiatives designed to improve the quality of life and standards of care for patients
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
Subscribe To Our Newsletter & Stay Updated
